Combining SPH4336 with endocrine therapy for breast cancer patients with brain metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and efficacy of SPH4336 tablets when used alongside endocrine therapy in patients suffering from breast cancer that has spread to the brain. It aims to determine how well this combination treatment works for patients who are not candidates for radical surgeries or other local therapies. Participants must have measurable lesions and meet specific health criteria to ensure their safety during the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients who voluntarily participate in this study, completely understand this study, and voluntarily sign the informed consent form (ICF).
2. ECOG (Eastern Cooperative Oncology Group) performance status score of 0 or 1.
3. Life expectancy ≥ 3 months.
4. Patients with locally advanced or metastatic breast cancer who are unable to receive radical surgeries/other local therapies.
5. At least one measurable lesion .
6. Laboratory test results meet the relevant requirements for organ function.
7. Subjects who agree to take effective contraceptive measures.

Exclusion Criteria:

1. Inflammatory breast cancer.
2. Patients unsuitable for endocrine therapy at the investigator's discretion.
3. Have a History of other malignancies prior to the start of study treatment.
4. Taking anti-tumor traditional Chinese patent medicines at the time of signing the ICF.
5. Patients who underwent a surgery prior to the start of study treatment, and have not yet recovered from adverse reactions of the surgery.
6. Patients who participated in a clinical trial and received other investigational drugs before the start of study treatment.
7. Pregnant or lactating women.
8. History of myocardial infarction, unstable angina pectoris, severe arrhythmia, and symptomatic congestive heart failure before the start of study treatment; ≥ NYHA (New York Heart Association) Class II; QTcF≥ 470 ms; left ventricular ejection fraction ≤ 50%.
9. History of ischemic stroke or severe thromboembolic disease before the start of study treatment.
10. Hepatitis B surface antigen positive and HBV (Hepatitis B Virus) DNA \> 2,000 IU/mL or \> 10(4) copies/mL; HCV (Hepatitis C Virus) antibody positive and HCV RNA positive; or known HIV infection.
11. History of severe allergic diseases, history of severe drug allergies, or known allergy to any ingredient of the investigational product.
12. Presence of diseases or conditions that may impact drug administration or gastrointestinal absorption before the start of study treatment.
13. Presence of uncontrolled infections before the start of study treatment.
14. Known history of drug abuse, excessive drinking, or illegal drug use; history of confirmed neurological or mental disorders.
15. Presence of other diseases that the risks of receiving the study treatment outweigh its benefits, as determined by the investigator, or any other reason for which patients are ineligible for the study as assessed by the investigator.

Where it's running

• Anhui provincial hospital
  Hefei, Anhui, China Recruiting
• The First Affiliated Hospital of Anhui Medical University
  Hefei, Anhui, China Recruiting
• Affiliated Cancer Hospital, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting
• Liuzhou people's Hospital
  Liuzhou, Guangxi, China Recruiting
• Anyang Cancer Hospital
  Anyang, He'nan, China Recruiting
• The First Affiliated Hospital of Henan University of Science and Technology
  Luoyang, He'nan, China Recruiting

Study contacts

• Study coordinator: Shusen Wang
• Email: wangshs@sysucc.org.cn
• Phone: 0086-020-87343811

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining SHR-A1811, Pyrotinib, and Bevacizumab for Advanced Breast Cancer with Brain Metastasis

  This study is testing a new combination of three drugs to see if it can help people with advanced breast cancer that has spread to the brain feel better and improve their treatment outcomes.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT06718933

• Ga68-PSMA PET/CT to tell radiation damage from tumor growth in brain metastases

  This project will test whether a Ga68-PSMA PET/CT scan can tell radiation necrosis apart from tumor regrowth in adults with brain metastases from lung cancer, melanoma, or breast cancer.

  Recruiting The Netherlands Cancer Institute · Amsterdam · NCT07511933

• Sacituzumab govitecan (Trop-2 ADC) for breast cancer that has spread to the brain

  This real-world project will try sacituzumab govitecan (a Trop‑2 antibody–drug conjugate) in adults with breast cancer brain metastases to see if it improves control of brain tumors and how safe it is in routine care.

  Recruiting Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT07251868

• Evaluating IAM1363 for HER2-related cancers

  This study is testing a new treatment called IAM1363 to see if it can help people with advanced cancers that have changes in the HER2 gene.

  Recruiting at 53 sites Phase 1 Iambic Therapeutics, Inc · La Jolla, California and 52 other locations · NCT06253871

• Treatment for HER2-negative breast cancer patients with brain metastases

  This study is testing a new treatment called utidelone, alone and with another drug, to see if it helps people with HER2-negative breast cancer that has spread to the brain.

  Recruiting at 12 sites Phase 2 Beijing Biostar Pharmaceuticals Co., Ltd. · Duarte, California and 11 other locations · NCT06764940

• Combination treatment for HER2-negative breast cancer brain metastasis

  This study is testing a new combination treatment for patients with HER2-negative breast cancer that has spread to the brain to see if it can help shrink tumors and improve survival.

  Recruiting Phase 2 Beijing 302 Hospital · Beijing, Beijing Municipality · NCT06418594

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.